CN109414403A - 口服胃滞留制剂及其用途 - Google Patents

口服胃滞留制剂及其用途 Download PDF

Info

Publication number
CN109414403A
CN109414403A CN201780041708.3A CN201780041708A CN109414403A CN 109414403 A CN109414403 A CN 109414403A CN 201780041708 A CN201780041708 A CN 201780041708A CN 109414403 A CN109414403 A CN 109414403A
Authority
CN
China
Prior art keywords
dosage unit
polymer
delivery device
pharmaceutical dosage
drug delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780041708.3A
Other languages
English (en)
Chinese (zh)
Inventor
N·纳冯
R·赖因伯格
Y·雅可夫森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indaptus Therapeutics Inc
Original Assignee
Intec Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59388117&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN109414403(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intec Pharma Ltd filed Critical Intec Pharma Ltd
Publication of CN109414403A publication Critical patent/CN109414403A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780041708.3A 2016-07-11 2017-07-11 口服胃滞留制剂及其用途 Pending CN109414403A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662360744P 2016-07-11 2016-07-11
US62/360,744 2016-07-11
PCT/IL2017/050783 WO2018011798A1 (en) 2016-07-11 2017-07-11 Oral gastroretentive formulations and uses thereof

Publications (1)

Publication Number Publication Date
CN109414403A true CN109414403A (zh) 2019-03-01

Family

ID=59388117

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780041708.3A Pending CN109414403A (zh) 2016-07-11 2017-07-11 口服胃滞留制剂及其用途

Country Status (17)

Country Link
US (1) US20190224118A1 (cg-RX-API-DMAC7.html)
EP (1) EP3481371A1 (cg-RX-API-DMAC7.html)
JP (1) JP2019527208A (cg-RX-API-DMAC7.html)
KR (1) KR20190026799A (cg-RX-API-DMAC7.html)
CN (1) CN109414403A (cg-RX-API-DMAC7.html)
AU (1) AU2017296351A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018077541A2 (cg-RX-API-DMAC7.html)
CA (1) CA3027700A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019000643A2 (cg-RX-API-DMAC7.html)
IL (1) IL264065A (cg-RX-API-DMAC7.html)
MX (1) MX2019000348A (cg-RX-API-DMAC7.html)
NZ (1) NZ750422A (cg-RX-API-DMAC7.html)
PH (1) PH12019500061A1 (cg-RX-API-DMAC7.html)
RU (1) RU2019103297A (cg-RX-API-DMAC7.html)
SG (2) SG10202100182TA (cg-RX-API-DMAC7.html)
WO (1) WO2018011798A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201900275B (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114796142A (zh) * 2022-04-08 2022-07-29 黄山学院 萘普生胃漂浮片及其制备方法
CN117224522A (zh) * 2023-11-15 2023-12-15 北京协和药厂有限公司 药物组合物及其制备方法、药物制剂

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018152334A1 (en) * 2017-02-15 2018-08-23 Molecular Infusions, Llc Formulations
BR102018002843A2 (pt) * 2018-02-09 2019-08-27 Prati, Donaduzzi & Cia Ltda composição farmacêutica e uso da mesma
WO2020037410A1 (en) * 2018-08-20 2020-02-27 Hexo Operations Inc. Cannabis-infused product with enhanced cannabinoid profile user experience
GB2584341B (en) * 2019-05-31 2023-03-01 Gw Res Ltd Cannabinoid formulations
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
CN114650809A (zh) 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
JP2022551730A (ja) 2019-10-14 2022-12-13 パイク セラピューティクス,インコーポレイテッド カンナビジオールの経皮送達
US20210177740A1 (en) * 2019-12-11 2021-06-17 Joel Studin Transpore delivery of cannabinoid and uses thereof
EP4084790A1 (en) * 2020-01-02 2022-11-09 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Floating drug delivery systems comprising cannabinoids
CA3217137A1 (en) 2021-04-29 2022-11-03 Christopher Adair Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
WO2023272335A1 (en) * 2021-06-30 2023-01-05 Emyria Cannabidiol formulation comprising a matrix pellet forming excipient
TW202430130A (zh) * 2022-10-18 2024-08-01 大陸商南京三迭紀醫藥科技有限公司 用於胃滯留的口服藥物劑型

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110092583A1 (en) * 2005-11-07 2011-04-21 Murty Pharmaceuticals, Inc. Oral Dosage Form Of Tetrahydrocannabinol And A Method Of Avoiding And/Or Suppressing Hepatic First Pass Metabolism Via Targeted Chylomicron/Lipoprotein Delivery
CN102149369A (zh) * 2008-04-18 2011-08-10 因泰克制药有限公司 卡比多巴/左旋多巴胃滞留给药
WO2012059815A1 (en) * 2010-11-01 2012-05-10 Intec Pharma Ltd. Accordion pill comprising levodopa for an improved treatment of parkinson's disease symptoms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03163011A (ja) * 1989-08-31 1991-07-15 Yamanouchi Pharmaceut Co Ltd 胃内滞留デバイス
IL133196A0 (en) * 1999-11-29 2001-03-19 Yissum Res Dev Co Gastroretentive controlled release pharmaceutical dosage forms
US10004684B2 (en) * 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
PT1903866E (pt) 2005-11-07 2016-06-09 Murty Pharmaceuticals Inc Distribuição melhorada de tetra-hidrocanabinol
DK2997953T3 (en) 2006-01-18 2019-04-15 Intec Pharma Ltd ADMINISTRATION ORAL ADMINISTRATION
WO2010064139A2 (en) * 2008-12-04 2010-06-10 Intec Pharma Ltd. Zaleplon gastroretentive drug delivery system
WO2011048494A2 (en) 2009-10-19 2011-04-28 Intec Pharma Ltd. Novel gastroretentive dosage forms of poorly soluble drugs
US8808734B2 (en) 2011-07-11 2014-08-19 Full Spectrum Laboratories Limited Cannabinoid formulations
KR20160002709A (ko) * 2013-02-12 2016-01-08 코버스 파마수티컬스, 아이엔씨. 초고순도 테트라하이드로카나비놀-11-오익산
WO2015025312A1 (en) 2013-08-21 2015-02-26 Cannabics Pharmaceuticals Inc Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110092583A1 (en) * 2005-11-07 2011-04-21 Murty Pharmaceuticals, Inc. Oral Dosage Form Of Tetrahydrocannabinol And A Method Of Avoiding And/Or Suppressing Hepatic First Pass Metabolism Via Targeted Chylomicron/Lipoprotein Delivery
CN102149369A (zh) * 2008-04-18 2011-08-10 因泰克制药有限公司 卡比多巴/左旋多巴胃滞留给药
WO2012059815A1 (en) * 2010-11-01 2012-05-10 Intec Pharma Ltd. Accordion pill comprising levodopa for an improved treatment of parkinson's disease symptoms

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JIE OONG ET AL: ""Current Pharmaceutical Treatments and Alternative Therapies of Parkinson"s Oisease"", 《CURRENT NEUROPHARMACOLOGY》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114796142A (zh) * 2022-04-08 2022-07-29 黄山学院 萘普生胃漂浮片及其制备方法
CN117224522A (zh) * 2023-11-15 2023-12-15 北京协和药厂有限公司 药物组合物及其制备方法、药物制剂
CN117224522B (zh) * 2023-11-15 2024-02-23 北京协和药厂有限公司 药物组合物及其制备方法、药物制剂

Also Published As

Publication number Publication date
JP2019527208A (ja) 2019-09-26
CA3027700A1 (en) 2018-01-18
ZA201900275B (en) 2020-05-27
NZ750422A (en) 2021-10-29
BR112018077541A2 (pt) 2019-04-30
SG11201811209QA (en) 2019-01-30
WO2018011798A1 (en) 2018-01-18
PH12019500061A1 (en) 2019-10-14
MX2019000348A (es) 2019-03-28
RU2019103297A3 (cg-RX-API-DMAC7.html) 2020-11-06
SG10202100182TA (en) 2021-02-25
AU2017296351A1 (en) 2019-02-28
EP3481371A1 (en) 2019-05-15
KR20190026799A (ko) 2019-03-13
CO2019000643A2 (es) 2019-04-30
RU2019103297A (ru) 2020-08-11
IL264065A (en) 2019-01-31
US20190224118A1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
US20190224118A1 (en) Oral gastroretentive formulations and uses thereof
KR101411100B1 (ko) 친지성 약물을 함유하는 나노캡슐을 포함하는 미소구체
CA2438097C (en) Cannabinoids pharmaceutical formulations
Musthaba et al. Status of novel drug delivery technology for phytotherapeutics
AU2006311818B2 (en) Improved delivery of tetrahydrocannabinol
DK2432455T3 (en) A composition comprising oil droplets
US20160184258A1 (en) Oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
JP2019527208A5 (cg-RX-API-DMAC7.html)
WO2016022936A1 (en) An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
WO2012033478A1 (en) An improved oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
CN1228020A (zh) 多层渗透装置
Zeng et al. Optimization of the process variables of tilianin-loaded composite phospholipid liposomes based on response surface-central composite design and pharmacokinetic study
US20050037073A1 (en) Solid self-emulsifying dosage form for improved delivery of poorly soluble hydrophobic compounds and the process for preparation thereof
US20150342893A1 (en) Celecoxib formulations useful for treating colorectal cancer
AU2016203127A1 (en) An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
Gottemukkula et al. SNEDDS as lipid-based nanocarrier systems: Concepts and formulation insights
WO2024142045A1 (en) Controlled-release oral formulations of lipophilic drugs
HK1261258A1 (zh) 口服胃滞留制剂及其用途
CA2533400A1 (en) Cannabinoids pharmaceutical formulations
Naser Depot-forming Microarray Patches for the Long-acting Delivery of Atorvastatin
Salooria et al. Solid Lipid Nanoparticles based Hydrogel of Mycophenolate Mofetil for the treatment of Psoriasis
Rani Nanoparticles Based Transdermal Patches for the Treatment of Schizophrenia
WO2015176780A1 (en) Celecoxib formulations useful for treating colorectal cancer
CN118103032A (zh) 包括氘代丁苯那嗪的多微粒剂型
HK1159475B (en) Scf extract containing cardiac glycoside

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1261258

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190301

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1261258

Country of ref document: HK